We expected to explore the DEGs between siAKT and progesterone treatment by bioinformatics, and to evaluate these DEGs in PR-positive endometrial carcinoma tissues with prognostic information, so as to identify the more specific therapeutic targets, which may improve the clinical treatment response for endometrial cancer patients. This evidence concerns the gene PGR and endometrial carcinoma.